REFERENCES


ANDO Y, TABEI K, SHIINA A, ASANO Y & HOSODA S (1985) Ultrasonographic evaluation of changes in the inferior vena caval configuration during hemodialysis:
Relationship between the amount of water removed and the diameter of the inferior vena cava. *Jap J Soc Dial Ther*, 18, 173-179.


Determinants of accelerated progression of arterial stiffness in normotensive and treated hypertensive subjects over a 6-year period. *Circulation*, 105, 1202-1207.


CHOBANIAN AV, BAKRIS GL, BLACK HR, CUSHMAN WC, GREEN LA, IZZO JL JR, JONES DW, MATERSON BJ, OPARIL S, WRIGHT JT JR, ROCCELLA EJ & NATIONAL HEART, L., AND BLOOD INSTITUTE JOINT NATIONAL
COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE, NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM COORDINATING COMMITTEE, (2003)


stresses and wall stress-mass-heart rate products in hypertensive patients with
electrocardiographic left ventricular hypertrophy: the LIFE study. Journal of
Hypertension, 18, 1129-1138.

effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac
fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early

ERTUK S, ERTUG A, ATES K, DUMAN N, ASLAN SM, NERGISOGLU G, DIKER E,
pressure monitoring data to echocardiographic findings in haemodialysis patients.

ERTURK, ERTUG AE, ATES K, DUMAN N, ASLAN SM, NERGISOGLU G, DIKER E,
pressure monitoring data to echocardiographic findings in haemodialysis patients.
Nephrol Dial Transpl, 11, 2050-2054.


ESCHBACH JW, AQUILING T, HALEY NR, FAN MH & BLAGG CR (1992) The long-
term effects of recombinant human erythropoietin on the cardiovascular system. Clin
Nephrol., 38, S98-103.

pressures may predict left ventricular mass as well as ambulatory monitoring. A meta-analysis

FAGARD RH, STAESSEN JA & THIJS L (1997) Prediction of cardiac structure and function by
repeated clinic and ambulatory blood pressure. Hypertension, 29, 22-29.
FAGUGLI RM, PALUMBO B, RICCIARDI D, PASINI P, SANTIROSIO P, VECCHI L,
and extracellular water in hemodialysis patients. *Nephron Clin Pract.*, 95, c60-6.

FOLEY RN, MURRAY AM, LI S, HERZOG CA, MCBAN AM, EGGERS PW &
COLLINS AJ (2005) Chronic kidney disease and the risk for cardiovascular disease,

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MARTIN CJ, MURRAY DC &
BARRE PE (1995) Clinical and echocardiographic disease in patients starting end-

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC & BARRE PE
(1996) Impact of hypertension on cardiomyopathy, morbidity and mortality in end-

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC & BARRE PE
(1996) The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage

FOLEY RN, PARFREY PS, MORGAN J, BARRE PE, CAMPBELL P, CARTIER P,
COYLE D, FINE A, HANDA P, KINGMA I, LAU CY, LEVIN A, MENDELSSOHN
Effect of haemoglobin levels in haemodialysis patients with asymptomatic


PARFREY PS, FOLEY RN, HARNETT JD, KENT GM, MURRAY DC & BARRE PE

PARFREY PS, FOLEY RN, HARNETT JD, KENT GM, MURRAY DC & BARRE PE


PORTOLES J, TORRALBO A, MARTIN P, RODRIGO J, HERRERO J & BARRIENTOS A


VICKERY S, PRICE CP, JOHN RI, ABBAS NA, WEBB MC, KEMPSON ME & LAMB EJ (2005) B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in Patients


